Review Papers Claim by Claim

Visual-first key findings (paper-centered)

• Non‑induced proviruses: The paper highlights Siliciano group's CROI 2013 report that a substantive fraction of non‑induced proviruses are intact and replication‑competent — implying the latent reservoir size could be 40–50× larger than prior estimates and many proviruses are not silenced by classical epigenetic marks Paper: Siliciano CROI summary
• Anatomical sanctuaries: GALT and lymphoid tissues are emphasized as major reservoirs with higher HIV‑DNA than blood during suppressive ART and low ARV penetration in some tissues, limiting eradication prospects Paper: anatomical reservoirs and drug penetration
• Cellular reservoir complexity: Long‑lived memory populations (TCM, TTM, newly described Tscm) and Tfh cells in follicles are singled out as durable reservoirs with self‑renewal/homeostatic proliferation contributing to persistence Paper: memory subsets & Tscm/Tfh reservoirs
• Interventions with limited effect (as of 2013): Vorinostat transiently increased transcription but did not reduce HIV‑DNA; ART intensification (raltegravir+maraviroc) did not decrease total HIV‑DNA in peripheral blood in published trials; IL‑7 and PD‑1 pathway modulation were described as plausible but unproven strategies Paper: therapeutic interventions status 2013
• Clinical cure evidence is exceptional and not scalable: the single CCR5Δ32/Δ32 stem‑cell transplant case and similar transplants were noted as instructive but impractical population‑level cure strategies Paper: CCR5Δ32 HSCT discussion

Critical evaluation (evidence, limitations, blind spots)

• Strengths: Clear, concise synthesis of state‑of‑the‑art 2013 evidence; identifies precise research priorities (assay standardization, tissue penetration, characterizing non‑induced proviruses) and maps immunovirological challenges to practical trial designs Paper: strengths and recommendations
• Limitations / biases: No new experimental data; reliance on conference abstracts and early trials (some results preliminary); as an opinion piece it is subject to selection bias in cited studies and lacks systematic methods or meta‑analytic weighting; the claim that non‑induced proviruses raise reservoir estimates 40–50× depends on early, complex assays subject to later reinterpretation Paper: limitation – opinion format
• Known unknowns (2013→now): How many intact proviruses are inducible in vivo; long‑term impact of repeated latency reversal combined with immune clearance; precise contribution of macrophages/other cell types across tissues; the role of clonal expansion of infected cells versus new cycles of replication in maintaining reservoir size Paper: gaps and unknowns

Actionable research priorities (derived)

1. Standardize and validate assays that quantify intact vs defective proviruses across blood and tissues (intact proviral DNA assay, viral outgrowth assays, tissue sampling protocols) Paper: assay standardization call
2. Develop ARV formulations and delivery systems with demonstrably improved penetration into GALT and lymphoid tissues and quantify drug levels in sanctuaries in trials Paper: tissue drug penetration
3. Combine latency reversal with immune enhancement (e.g., therapeutic vaccines, checkpoint blockade, adoptive cell approaches) and measure both proviral induction and clearance in tissues, not only blood Paper: combine LRA + immunotherapy

Author reviews